Zacks Investment Research downgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) from a hold rating to a sell rating in a research report sent to investors on Thursday morning, Zacks.com reports.

According to Zacks, “Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. “

A number of other analysts also recently weighed in on the stock. Wedbush set a $11.00 price target on shares of Sangamo Therapeutics and gave the company a hold rating in a research report on Monday, July 8th. ValuEngine downgraded shares of W&T Offshore from a hold rating to a sell rating in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Hold and an average price target of $13.33.

Sangamo Therapeutics stock opened at $11.72 on Thursday. The company has a current ratio of 3.98, a quick ratio of 3.98 and a debt-to-equity ratio of 0.04. Sangamo Therapeutics has a 1 year low of $6.26 and a 1 year high of $19.25. The firm has a market cap of $1.35 billion, a P/E ratio of -16.74 and a beta of 2.98. The company’s 50-day simple moving average is $10.03.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.14). Sangamo Therapeutics had a negative net margin of 113.03% and a negative return on equity of 24.67%. The business had revenue of $8.07 million for the quarter, compared to analyst estimates of $27.21 million. On average, research analysts expect that Sangamo Therapeutics will post -1.46 earnings per share for the current fiscal year.

In related news, CFO Kathy Yi sold 5,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $10.00, for a total value of $50,000.00. Following the sale, the chief financial officer now directly owns 30,512 shares in the company, valued at approximately $305,120. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.30% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. California Public Employees Retirement System raised its holdings in Sangamo Therapeutics by 25.9% during the 4th quarter. California Public Employees Retirement System now owns 132,230 shares of the biopharmaceutical company’s stock worth $1,518,000 after buying an additional 27,200 shares during the period. Hsbc Holdings PLC acquired a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $752,000. Sphera Funds Management LTD. acquired a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $3,903,000. First Trust Advisors LP raised its holdings in Sangamo Therapeutics by 48.9% during the 4th quarter. First Trust Advisors LP now owns 113,661 shares of the biopharmaceutical company’s stock worth $1,305,000 after buying an additional 37,344 shares during the period. Finally, Bailard Inc. raised its holdings in Sangamo Therapeutics by 373.0% during the 1st quarter. Bailard Inc. now owns 156,100 shares of the biopharmaceutical company’s stock worth $1,489,000 after buying an additional 123,100 shares during the period. Institutional investors and hedge funds own 57.18% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

See Also: If I purchase shares through a brokerage account, am I the holder of record?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.